KPC Pharmaceuticals Inc (600422) - Total Liabilities
Based on the latest financial reports, KPC Pharmaceuticals Inc (600422) has total liabilities worth CN¥5.15 Billion CNY (≈ $753.67 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
KPC Pharmaceuticals Inc - Total Liabilities Trend (1997–2024)
This chart illustrates how KPC Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. See KPC Pharmaceuticals Inc (600422) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
KPC Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of KPC Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
AAEON Technology Inc
TW:6579
|
Taiwan | NT$2.96 Billion |
|
Hangzhou Huning Elevator Parts Co Ltd
SHE:300669
|
China | CN¥130.47 Million |
|
CRA International Inc
NASDAQ:CRAI
|
USA | $464.02 Million |
|
Beijing Bayi Space LCD Technology Co Ltd
SHG:688181
|
China | CN¥1.10 Billion |
|
Pearl Global Industries Limited
NSE:PGIL
|
India | Rs18.07 Billion |
|
Shanghai Xinpeng Industry Co Ltd
SHE:002328
|
China | CN¥1.82 Billion |
|
Domino's Pizza Enterprises Limited
F:HQX
|
Germany | €2.01 Billion |
|
Qualipoly Chemical Corp
TW:4722
|
Taiwan | NT$3.60 Billion |
Liability Composition Analysis (1997–2024)
This chart breaks down KPC Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see KPC Pharmaceuticals Inc (600422) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.93 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.97 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.43 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how KPC Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for KPC Pharmaceuticals Inc (1997–2024)
The table below shows the annual total liabilities of KPC Pharmaceuticals Inc from 1997 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥5.87 Billion ≈ $858.25 Million |
+43.44% |
| 2023-12-31 | CN¥4.09 Billion ≈ $598.32 Million |
-4.68% |
| 2022-12-31 | CN¥4.29 Billion ≈ $627.68 Million |
+8.52% |
| 2021-12-31 | CN¥3.95 Billion ≈ $578.39 Million |
+12.31% |
| 2020-12-31 | CN¥3.52 Billion ≈ $515.01 Million |
+13.50% |
| 2019-12-31 | CN¥3.10 Billion ≈ $453.74 Million |
+5.36% |
| 2018-12-31 | CN¥2.94 Billion ≈ $430.67 Million |
+14.76% |
| 2017-12-31 | CN¥2.56 Billion ≈ $375.26 Million |
+43.25% |
| 2016-12-31 | CN¥1.79 Billion ≈ $261.97 Million |
+11.03% |
| 2015-12-31 | CN¥1.61 Billion ≈ $235.95 Million |
+65.48% |
| 2014-12-31 | CN¥974.40 Million ≈ $142.59 Million |
-3.20% |
| 2013-12-31 | CN¥1.01 Billion ≈ $147.31 Million |
-8.07% |
| 2012-12-31 | CN¥1.10 Billion ≈ $160.24 Million |
+53.72% |
| 2011-12-31 | CN¥712.37 Million ≈ $104.24 Million |
+19.56% |
| 2010-12-31 | CN¥595.84 Million ≈ $87.19 Million |
+17.80% |
| 2009-12-31 | CN¥505.79 Million ≈ $74.01 Million |
+3.97% |
| 2008-12-31 | CN¥486.48 Million ≈ $71.19 Million |
-12.34% |
| 2007-12-31 | CN¥554.98 Million ≈ $81.21 Million |
+1.94% |
| 2006-12-31 | CN¥544.44 Million ≈ $79.67 Million |
-16.28% |
| 2005-12-31 | CN¥650.31 Million ≈ $95.16 Million |
+44.92% |
| 2004-12-31 | CN¥448.75 Million ≈ $65.67 Million |
+56.49% |
| 2003-12-31 | CN¥286.76 Million ≈ $41.96 Million |
+49.26% |
| 2002-12-31 | CN¥192.11 Million ≈ $28.11 Million |
-5.94% |
| 2001-12-31 | CN¥204.24 Million ≈ $29.89 Million |
-15.31% |
| 2000-12-31 | CN¥241.15 Million ≈ $35.29 Million |
-18.03% |
| 1999-12-31 | CN¥294.19 Million ≈ $43.05 Million |
+10.99% |
| 1998-12-31 | CN¥265.06 Million ≈ $38.79 Million |
+53.98% |
| 1997-12-31 | CN¥172.13 Million ≈ $25.19 Million |
-- |
About KPC Pharmaceuticals Inc
KPC Pharmaceuticals,Inc., a pharmaceutical company, engages in the research and development, production, marketing, and commercial wholesale of botanical drugs and natural drugs in the People's Republic of China and internationally. It offers artemisia annua series, panax notoginseng, gastrodia, artemether, specialty herbal, fine Chinese, and classic prescription for bones and joint, antibiotics,… Read more